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Abstract 
 
Staphylococcus aureus is a leading cause of septicaemia-related death. 
The aims of this thesis were to describe the epidemiology of invasive 
Staphylococcus aureus infections (ISA), the clinical course, and serological 
response in ISA in a prospective, population-based study. The antibody response 
was compared with the serological findings in healthy individuals. 
 
During two years 170 episodes of ISA were registered, with an incidence of 33.9 
cases/100,000/year. Haemodialysis (relative risk 291) and peritoneal dialysis 
(relative risk 204) patients were at the highest risk. Soft tissue infections, 
bacteraemia without focus, infections of intravenous lines, and joint/bone infections 
were the most common diagnoses. The spectrum of signs and symptoms was wide, 
with nearly a quarter of the patients being afebrile. 
 
The mortality rate was 19.1% (28-day mortality), with an annual population 
mortality of 5.9/100,000. Patients with complicated bacteraemia (32% of all 
episodes) had a mortality rate of 32%, and patients with severe sepsis (30% of all 
episodes) 54%. Patients with bacteraemia without focus, patients with respiratory 
infections, and patients with endovascular infections had the highest mortality 
figures. 
 
Only severe sepsis and low systolic blood pressure were independent factors for 
mortality in a multivariable regression model. We found a relapse rate of 9.3%, and 
a rate of remaining symptoms after the antibiotic treatment had ended of 34%. 
Sequelae were seen among 60% of the patients with arthritis. 
The frequency of different agr, accessory gene regulator, groups within the 
bacterium, was not correlated to the disease presentation. 
 
The antibody response in ISA showed a great variability. Patients with a fatal 
outcome produced lower amounts of antibodies to all antigens, and significantly to 
four antigens (teichoic acid, lipase, enterotoxin A, and scalded skin syndrome 
toxin). The same trend was noted for patients with a complicated course of 
infection. 
 
Healthy carriers of S. aureus in the nares had higher levels of antibodies to all 
eleven tested antigens, and significantly to five (teichoic acid, lipase, enterotoxin A, 
toxic shock toxin-1, and extracellular adherence protein) than non-carriers. Ages 
over 65y showed only slightly lower levels. 
 
Keywords: Staphylococcus aureus, epidemiology, risk factors, clinical presentation, 
mortality, recurrence, sequelae, agr, serology, colonization. 
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Abbreviations 
 
agr  accessory gene regulator 
AFLP  Amplified Fragment Length Polymorphism 
ASTA  Antistapholysin assay 
AT  Alpha toxin 
Bsp  Bone sialoprotein binding protein 
CA MRSA Community-acquired methicillin resistant Staphylococcus 
aureus 
CA MSSA Community-acquired methicillin sensitive Staphylococcus 
aureus 
ClfA Clumping factor A 
ClfB Clumping factor B 
CP Capsular polysaccharides 
Eap Extracellular adherence protein 
EARSS European Antibiotic Resistance Surveillance System 
Efb Extracellular fibrinogen binding protein 
IgG Immunoglobulin G 
ISA Invasive Staphylococcus aureus infections 
Isd Iron-responsive surface determinant  
MLST Multi Locus Sequence Typing 
MSCRAMM Microbial Surface Components Recognizing Adhesive 
Matrix Molecules 
PCR Polymerase chain reaction  
PFGE Pulsed-field gel electrophoresis 
PVL Panton-Valentin leucocidin  
SAB Staphylococcus aureus bacteraemia 
Sag Superantigens 
SCCmec Staphylococcal chromosomal cassette mec 
SCV Small colony variants 
SEA Staphylococcal enterotoxin A 
spa Staphylococcal protein A 
SSS Staphylococcal scalded skin toxin 
TA Teichoic acid 
TST Toxic Shock Toxin-1 
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Introduction 
S. aureus 
Staphylococcus aureus is a unique microorganism as compared with other 
clinically relevant bacteria in three respects. The organism expresses a variety of 
virulence factors. The bacterium continues to demonstrate the ability to develop 
resistance to include a broad array of antimicrobial classes, and S. aureus is a 
prominent pathogen in both hospital and the community settings. 
 
The number of serious infections with Staphylococcus aureus is increasing; this is 
true for both community-acquired (CA) and nosocomial infections. S. aureus was 
diagnosed in 1% of all discharge diagnoses in hospitals in the USA in 2003, with 3 
times the length of hospital stay, 3 times the total charges, and 5 times the risk of 
in-hospital death as compared with stays without this diagnosis in 200/2001 
(Noskin, Rubin et al. 2005; Noskin, Rubin et al. 2007). Different medical 
disciplines face complicated S. aureus infections in different patient categories, 
from newborns to the elderly, and from immunocompetent to immunosuppressed 
patients. In spite of advances in diagnosis and treatment, mortality and 
complication rates are still high, with reports of in-hospital mortality of more than 
20% (Seifert, Wisplinghoff et al. 2008). 
 
There is no vaccine available, and the role of passive immunprophylaxis is unclear. 
The population at risk increases with more elderly people and more patients 
receiving imunosuppression or having indwelling catheters and other foreign 
materials. 
 
The numbers of resistant bacteria, MRSA (methicillin resistant S. aureus) are 
rising. Within a year after the introduction of semi-synthetic penicillins such as 
methicillin, there were reports of resistant isolates in 1961 (Jevons 1961). MRSA 
was initially confined to hospitals, with increasing reports of outbreaks all over the 
world, and with the search-and-destroy-strategy the epidemic was controlled. 
During the 1990s the situation changed, with endemic clones in hospitals being 
established, and a sharp increase in the rate of MRSA-bacteraemia and 
postoperative infections (Diekema, Pfaller et al. 2001; Wisplinghoff, Bischoff et al. 
2004). In the last decade, CA MRSA infections have become prevalent in many 
locations around the world (Fridkin, Hageman et al. 2005; Tenover 2006; Tristan, 
Ferry et al. 2007). Circulating CA strains of MRSA are genetically distinct from 
those traditionally detected in health care-associated infections, and often carry the 
genes encoding Panton-Valentine leukocidin (Orscheln, Hunstad et al. 2009). This 
exotoxin causes severe necrosis in skin, soft-tissue and lungs, resulting in serious 
infections, with a fatal outcome in some cases. 
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The entire genome of S. aureus was sequenced in 2001 (Kuroda, Ohta et al. 2001) 
and ongoing molecular and genetic dissection of S. aureus has revealed a large 
number of surface adhesins, which mediate adherence to and colonization of target 
tissue, and secreted enzymes and toxins that make invasion possible. S. aureus 
harbour a number of mobilizable exogenous DNA stretches, including insertion 
sequences, transposons, bacteriophages, and pathogenicity islands (also referred to 
as genomic islands) (Ruzin, Lindsay et al. 2001; Baba, Takeuchi et al. 2002; 
Novick 2003), which contain specific determinants responsible for disease and 
antibiotic resistance. These exogenous elements explain the high capacity of S. 
aureus to undergo horizontal gene transfer and to exchange genetic elements with 
other organisms, including both staphylococcal and nonstaphylococcal genera. 
Because gene exchange is a key player in evolution, this genetic plasticity is a 
probable explanation for the success of S. aureus as both a colonizer and a disease-
producing microbe. 
 
Epidemiology of S. aureus infections 
S. aureus was the most prevalent species isolated from inpatient isolates, 
irrespective of origin, (18.7% of all bacterial isolates) and the second most 
prevalent ( 14.7%) from outpatient isolates in a laboratory-based surveillance in 
USA from 1998 to 2005 (Styers, Sheehan et al. 2006). The most common 
organisms causing nosocomial bacteraemia were coagulase negative staphylococci 
(31% of isolates) and S. aureus (20%) in a nationwide hospital surveillance study in 
the USA from 1995 to 2002 (Wisplinghoff, Bischoff et al. 2004). S. aureus was 
second to E.coli in a populations-based study of blood stream infections, both 
among all isolates and among CA infections (Uslan, Crane et al. 2007). The 
incidence of S. aureus bacteraemia (SAB) has increased in recent years in the 
United States and in Europe (Shorr 2007) (EARSS 2008). The incidence of SAB 
doubled in England between 1993 and 2002, mostly owing to a huge increase in 
MRSA infections, but also due to an increase in MSSA (methicillin sensitive S. 
aureus) bacteraemia (Johnson, Pearson et al. 2005). 
 
The incidence of SAB is not known in Sweden since this is not a mandatory 
reportable disease, but approximations based on data reported to EARSS (European 
Antibiotic Resistance Surveillance System) claims a figure of 2,195 cases per year 
(Melander, Burman et al. 2007), i.e. 24.3/100,000 population. 
 
The epidemiology of invasive Staphylococcus aureus infections (ISA), i.e. not only 
bacteraemia, has only been defined in few studies of population-based study 
design. Other studies have been limited either by inclusion of only selected patients 
with ISA or by failure to include clinical information (Jensen, Wachmann et al. 
1999; Morin and Hadler 2001). Laupland conducted a population-based 
surveillance of all invasive S. aureus infections occurring in the Calgary Health 
Region in Canada from 1999-2001, and estimated an incidence of 28.4 
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cases/100,000 population (17.9/100,000 population, for bacteraemia), of which 
46% were classified as nosocomial (Laupland, Church et al. 2003). 
 
S. aureus is responsible for 25% to 68% of cases of native endocarditis in adults, 
and the proportion is increasing (Miro, Anguera et al. 2005). 
 
Bone and joint infections attributable to S. aureus are also increasing in number. 
Between 2000 and 2004 the incidence of acute osteoarticular infections in children 
rose from 2.6/1,000 admissions to 6/1,000 in a university hospital in USA, with 
MSSA being responsible for 10%-13% and the proportion of MRSA increasing 
from 4% to 40% (Arnold, Elias et al. 2006). Laupland (Laupland, Church et al. 
2003) reported an annual rate of arthritis of 2.4/100,000 population. 
 
Risk factors for ISA 
Several conditions have been identified as associated with ISA, including diabetes, 
alcohol abuse, immunosuppression, nasal colonization by S. aureus, admission to 
hospital or intensive care unit, intravenous drug abuse, haemodialysis, HIV 
infection, older age, newborn, male, use of intravenous cannulas, ot the presence of 
a foreign body (Lowy 1998; Steinberg, Heling et al. 1999). Laupland (Laupland, 
Church et al. 2003) quantified risk factors, and found the highest risk for 
haemodialysis patients (relative risk 257), peritoneal dialysis (RR 150), HIV-
infection (RR 24), and solid organ transplantation (RR 21). The distribution and 
magnitude of comorbidity risk factors for acquiring MRSA and MSSA are 
comparable (Laupland, Ross et al. 2008). 
 
Individuals lacking antibodies against TST (Toxic Shock Syndrome Toxin-1) are at 
risk of developing toxic shock (Parsonnet, Hansmann et al. 2005) (Lappin and 
Ferguson 2009). It has been hypothezid that mutations in the innate immune 
system, Toll-Like Receptor 2 Gene, may predispose to ISA (Mullaly and Kubes 
2006). 
 
Clinical presentation 
ISA has a broad clinical presentation from bacteraemia with unknown focus to 
bacteraemia with a primary focus such as skin and soft tissue infection, arthritis, 
skeletal infection, deep abscesses from various organs, respiratory infection, and 
urinary tract infection. S. aureus can also present as a toxin-mediated disease 
without bacteraemia or a focal infection as toxic shock syndrome, scalded-skin 
syndrome, neonatal toxic shock syndrome-like exanthematous disease, or food 
poisoning. 
 
The risk of a secondary or a metastatic focus such as endocarditis or other 
endovascular focus, arthritis, skeletal infection, CNS-infection, abscesses in various 
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organs is characteristic. Presence of a secondary focus defines complicated 
infections, and it is crucial to successful management of ISA to separate 
uncomplicated from complicated infections owing to the need for different 
therapies and follow up. This clinical decision-making may, in theory, be simple 
and straightforward but in clinical practice it is difficult to perform. For example, in 
a report of 260 patients with SAB owing to endocarditis, the diagnosis of 
endocarditis was not clinically suspected and was first detected at autopsy in 32% 
of patients (Roder, Wandall et al. 1999). Risk factors for complicated infections 
have been evaluated by many researchers (Fowler, Olsen et al. 2003; Troidle, Eisen 
et al. 2007). According to Fowler the strongest predictor for complicated SAB was 
a positive follow-up blood culture at 48 to 96 hours, and a scoring system based on 
the presence or absence of 4 risk factors (community acquisition, skin examination 
findings suggesting acute systemic infection, persistent fever at 72 hours, and 
positive follow-up blood culture results at 48-96 hours) accurately identified 
complicated SAB. 
 
In the ongoing worldwide epidemic of CA-MRSA it has been proposed that 
patients presenting to hospitals with risk factors for MRSA should receive 
empirical therapy covering MRSA. Unfortunately, clinical and epidemiological 
characteristics cannot distinguish CA-MRSA and CA-MSSA, as Miller (Miller, 
Perdreau-Remington et al. 2007) showed in a prospective investigation. MRSA 
infection was associated with younger age, skin/soft-tissue infection, snorting 
illegal drugs, recent incarceration, lower comorbidity index, more frequent visits to 
bars, rave parties, and clubs, but the sensitivity, specificity and predictive values 
were low. 
 
Wang found, in a study concerning CA-SAB, that independent risk factors for 
MRSA were cutaneous abscess (OR 5.46), and necrotizing pneumonia (OR 24.81), 
and an independent risk factor for MSSA was endovascular infection (Wang, Chen 
et al. 2008). 
 
Could virulence factors influence clinical presentation? In toxin-mediated diseases 
this is obvious, but among other ISA infections it is not clear. Hogevik (Hogevik, 
Soderquist et al. 1998) found the same virulence factors in isolates from 
endocarditis patients as in isolates from superficial skin infections. It has been 
claimed that virulence gene regulators, such as agr (accessory gene regulator), are 
associated with certain disease presentations (Jarraud, Mougel et al. 2002; Ben 
Ayed S 2006). 
 
Elderly patients have different clinical presentation than younger patients. 
McClelland (McClelland, Fowler et al. 1999) showed that it is more common to 
find afebrile elderly patients with SAB, patients aged 66-90y, but the white blood 
cell count did not differ compared to younger patients. The rate of pacemakers and 
prostheses was higher, but not the rate of unknown bacteraemia. 
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Mortality 
During the last two decades, mortality has declined for S. aureus bacteraemia. 
Benfield (Benfield, Espersen et al. 2007) reported a decrease in overall in-hospital 
mortality rate from 34% to 22% in the period 1981 to 2000 in Denmark. This 
decrease was more pronounced in nosocomial bacteraemia (from 36% to 21%) than 
in community-acquired bacteraemia (34% to 26%). In recent years no further 
decrease has been observed. Laupland (Laupland, Ross et al. 2008) noted 
unchanged annual mortality from 2000-2006, with a higher overall case fatality rate 
for patients with MRSA (39%) than for patients with MSSA (24%). This latter 
finding is in accordance with proof of the efficacy of early antibiotic therapy. 
Lodise (Lodise, McKinnon et al. 2003) demonstrated that delaying therapy for 45 h 
substantially increase the risk of infection-related mortality in patients with 
hospital-acquired S. aureus bacteraemia. 
 
Numerous studies have demonstrated higher mortality rates for MRSA-infections 
than for MSSA (Whitby, McLaws et al. 2001; Cosgrove, Sakoulas et al. 2003; 
Daskalaki, Otero et al. 2007). The unresolved question is whether or not this 
mortality difference is attributable to increased virulence for MRSA. Daskalki 
found no higher mortality for MRSA when adjusting the two groups for factors 
such as age, respiratory focus, and inappropriate antibiotic therapy. Nosocomial 
MRSA is still more common than CA-MRSA bacteraemia, although the latter is on 
the rise. Wang (Wang, Chen et al. 2008) registered the same mortality for CA-
MSSA bacteraemia as for CA-MRSA bacteraemia, with a hazard ratio for MRSA 
1.01, 95% CI 0.3-3.39. This was in spite of the fact that most patients with MRSA 
did not receive empirical glycopeptide treatment. 
 
Several predictive factors for mortality, such as acute severity of illness, respiratory 
focus, unknown focus, endovascular focus, meningitis, age, MRSA, presence of 
shock, inadequate treatment, underlying disease status, lack of source control, mode 
of acquisition, and infectious disease consultant, have been registered in varying 
degrees (Mylotte and Tayara 2000; Hill, Birch et al. 2001; Jensen, Wachmann et al. 
2002; Chang, Peacock et al. 2003; Kaech, Elzi et al. 2006). McClelland 
(McClelland, Fowler et al. 1999) reported an odds ratio for overall mortality in 
SAB for patients aged 66-90y of 2.21 as compared with patients aged 18-60y, 
adjusted for confounding factors, and an OR of 2.30 concerning death attributable 
to SAB. Nickerson concluded (Nickerson, Wuthiekanun et al. 2009), in a study on 
ISA in a developing country, that simple clinical measures such as drainage of pus 
and timely antibiotic therapy are key to the successful management of S. aureus 
infections, and that defining the presence of genes encoding PVL, for example, 
provides no practical bedside information and detracts attention away from 
identifying verified clinical risk factors and interventions that can save lives. 
 
Endocarditis is the complicated infection with the highest mortality, with figures 
ranging from 20% to 65% (Murray 2005), and with higher mortality for left-sided 
 14 
(38%) than right-sided (17%) endocarditis. S. aureus has been identified as an 
independent risk factor for mortality in large prospective studies of infective 
endocarditis of all causes (Cabell, Jollis et al. 2002). 
 
The mortality rate for osteomyelitis, not only caused by S. aureus, was 2.8% in a 
study by Tice (Tice, Hoaglund et al. 2003), and Shirtliff (Shirtliff and Mader 2002) 
reviewed the literature for acute septic arthritis and found mortality figures ranging 
from 5% to 20% irrespective of causative organism. 
 
Recurrence 
Recurrence is common, but incidence and risk factors for recurrence are uncertain. 
Chang (Chang, Peacock et al. 2003) noted a recurrence rate of 9.4% following 
SAB. Most were relapses with the same pulsed-field gel electrophoresis (PGFE) 
pattern. Duration of treatment was not found to be correlated to relapses. In 
contrast, Verhagen (Verhagen, van der Meer et al. 2003) demonstrated relatively 
high relapse rate in patients receiving less than 10 days of iv therapy for SAB, 18%. 
 
β-lactam antibiotics were found to be superior to vancomycin in efficacy in MSSA-
patients in the study by Chang. Failure to remove infected intravascular 
devices/catheters is common in patients experiencing multiple relapses (Chang, 
Peacock et al. 2003; Walker, Bowler et al. 2009). 
 
Small colony variants, SCV, of S. aureus have slow growth rates, persist 
inctracellularly, and are less susceptible to antibiotics. They are associated with 
persistent or relapsing osteomyelitis and device-related infections (Proctor, von Eiff 
et al. 2006). SCVs are often recovered from S. aureus strains that have been 
exposed to gentamicin or other aminoglyosides. 
 
Sequelae 
Sequelae or functional impairment have not been reported in large, retrospective or 
prospective surveys of both SAB and ISA (Laupland, Church et al. 2003; 
Fätkenheuer, Preuss et al. 2004). Fätkenheuer registered a crude mortality in SAB 
after 1 year of 37.6%, but provided no information on surviving patients. 
Zeylemaker (Zeylemaker, Jaspers et al. 2001) reported, in a study of catheter-
related SAB, favourable outcome in 20 of 49 patients. Also 17% of the patients 
developed a complication more than 3 months after treatment. The study was 
undertaken in a tertiary teaching hospital with selected high-risk patients. Davies 
(Davis 2005) reviewed the literature on bone and joint infections and concluded 
that 40-50% of patients have residual joint dysfunction after septic arthritis. 
 
O’Daly (O'Daly, Morris et al. 2008) described an adverse outcome in 66% of 
patients with pyogenic spinal infection, irrespective of causative organism, at a 
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median follow up of 61 months, 17% with neurologic deficits, and 17% with acute 
sepsis-related death. Delay in diagnosis of spinal infection and neurologic 
impairment at diagnosis were significant predictors of neurologic deficit at follow 
up. 
Accessory gene regulator 
Virulence of S. aureus is multifactorial, and attributable to the combined action of 
virulence determinants such as cell-surface proteins, secreted toxins, and enzymes. 
The expression of virulence factors is generally regulated in a growth phase 
dependent manner governed by the accessory gene regulator (agr) system (Janzon 
and Arvidson 1990) and by several DNA binding proteins including sarA 
homologues (Arvidson and Tegmark 2001). Agr functions via an auto-inducing 
peptide, AIP, and is activated in late and post-exponential growth. Agr mutants 
display reduced virulence in several animal models, including studies of arthritis, 
subcutaneous abscess, mastitis, endocarditis, and osteomyelitis, reviewed by 
Collins (Collins V.L. and Tarkowski 2000). S. aureus strains can be divided into 
four groups depending on the variants of the agr locus sequence, and strains 
belonging to different agr groups express different patterns of secreted virulence 
factors (Ji, Beavis et al. 1997). Strains belonging to the same agr group can cross-
activate each other via AIP, whereas cross-inhibition occurs between different agr 
groups, and also between strains from S. aureus and other staphylococci species 
such as Staphylococcus epidermidis. Simultaneous inoculation of inhibitory AIP 
with virulent S. aureus suppressed the lesions in a mouse subcutaneous abscess 
model (Mayville, Ji et al. 1999). 
 
It has been proposed that type of disease correlates with agr group. For example, 
Jarruad (Jarraud, Mougel et al. 2002) linked endocarditis with agr groups I and II, 
and toxic shock syndrome with agr group III. Ben Ayed (Ben Ayed S 2006) 
reported a relationship between agr group III and non-invasive infections, and 
between agr group I and invasive infections. Sakoulas (Sakoulas, Eliopoulos et al. 
2003) demonstrated a connection between agr group II and glycopeptide resistance. 
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Antibody response 
Diagnostic use 
The diagnosis of ISA is based on cultures from normally sterile body sites, most 
often blood. Sometimes there is a clinical suspicion of ISA but cultures are negative 
or impossible to obtain, e.g. from deep abscesses. In patients with bacteraemia it is 
necessary to differentiate between patients with complicated infections from those 
with an uncomplicated infection. In these settings serology against various S. 
aureus antigens has been tried. 
 
Healthy adults have detectable antibody levels against most S. aureus antigens 
(Espersen and Schiotz 1981). These antibodies develop during childhood, and adult 
antibody levels are generally reached by the age of 15 years (Granstrom, Julander 
et al. 1983; Julander, Granstrom et al. 1983; Christensson, Fehrenbach et al. 1985; 
Dryla, Prustomersky et al. 2005). The humoral immune response varies greatly 
during invasive infections (Colque-Navarro, Soderquist et al. 1998). Hence, the 
clinical value of diagnostic S. aureus serology is low. This is because of varying 
sensitivity, specificity, and insufficient predictive value of the tests or combinations 
of tests used. It is believed that complicated infections generate a higher antibody 
response than uncomplicated ones. Ryding (Ryding 2001) concluded in his thesis 
on S. aureus serology, however, that there is no evidence that any serological assay 
or combination of assays can distinguish between complicated and uncomplicated 
S. aureus infections. Sensitivity, defined as percentage of patients with S. aureus 
endocarditis or complicated bacteraemia with a positive outcome, has been found to 
vary from 36% to 100%. Specificity, defined as percentage of patients with 
uncomplicated S. aureus bacteraemia with a negative outcome, has been found to 
vary from 34% to 100% (Julander, Granstrom et al. 1983; Christensson, Espersen 
et al. 1985; Christensson 1986; Verbrugh, Peters et al. 1986; Ryding 2001). 
However, the reliability of the diagnosis of, for example, endocarditis in older 
studies can be questioned, because of the low use of echocardiography (no use of 
transeosophageal examination). The time of sampling also differs in different 
studies. In some studies samples in the first week after the start of illness is not 
considered, and in others the maximum titer is compared. In fact, it has been 
reported (Colque-Navarro, Soderquist et al. 1998) lower levels of antibodies against 
several antigens in patients with complicated bacteraemia as compared with 
patients with uncomplicated bacteraemia. 
 
Toxic shock syndrome attributable to TST producing S. aureus can be diagnosed 
serologically and by determination of specific toxin production from a patient’s 
isolate. 
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Protective immune activation 
Is the antibody response in human beings of a protective nature? S. aureus is 
mainly an extracellular pathogen, and host defence consequently relies mostly on 
innate immunological mechanisms supported by antistaphylococcal adaptive 
humoral responses. Individuals deficient in antibodies (hypo- and 
agammaglobunemies) and/or neutrophil function suffer from an increased 
frequency of staphylococcal infections (Liese, Jendrossek et al. 1996). 
 
However, an individual who has had a S. aureus infection is usually not protected 
from a subsequent infection in spite of detectable antibodies against various 
antigens. A critical step in the elimination of S. aureus in the humans is 
complement-mediated opsonisation (Cunnion, Zhang et al. 2003). It has been 
claimed that the vast majority of antibodies in healthy individuals, 60 to 85%, are 
induced by lipoteichoic acid, which fails to promote opsonisation (Dryla, 
Prustomersky et al. 2005; Peterson, Wilkinson et al. 1978). 
 
Gjertsson (Gjertsson, Hultgren et al. 2000) found no difference in outcome between 
mice deficient in B lymphocytes, i.e. with no IgG production, and congenic 
controls in a haematogenous arthritis model. Later, Gjertsson (Gjertsson, Kleinau et 
al. 2002) also showed that mice deficient in FcγII-receptor on B-lymphocytes had 
higher survival rates, and showed elevated serum levels of IgG antibodies against 
ClfA, increased levels of IL-10, and enhanced phagocytic capacity. FcγII-receptor 
mediates inhibitory signals, and activation of this receptor results in decreased B-
cell activation and proliferation. These results suggest that protective antibodies are 
produced during a S. aureus infection but to a relatively low extent, and that the 
massive increase in IgG production early on during the course of infection is of no 
protective value. Gjertsson’s (Gjertsson 2003) explanation for these assumptions is 
intriguing (Figure 1). The extensive early IgG-production is a result of the 
mitogenic and superantigenic stimulation of B cells provided by the bacterium, as 
well as the B cell response to thymus-independent antigens (i.e. no memory cells 
are produced). The antibodies are mainly of low affinity and have broad specificity, 
some with specificities for non-staphylococcal epitopes, including self-epitope. 
These antibodies may down-regulate the subsequent B cell response towards a 
thymus-dependent antigen by cross-linking the B-cell receptor (mediating 
stimulation) to a FcγII receptor. The antibodies formed early may also mask the 
protective epitopes, rendering them invisible to the B cells and thereby preventing 
further response. 
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Numerous experimental studies on animals have shown that it is possible to elicit a 
protective response to several different bacterial components, such as surface 
adhesin (ClfA, FnBp and collagen binding protein) (Flock 1999; Josefsson, 
Hartford et al. 2001; Rennermalm, Li et al. 2001; Hall, Domanski et al. 2003), 
surface polysaccharides (type 5 and 8) (Fattom, Sarwar et al. 1996) and secreted 
toxins (Nilsson, Verdrengh et al. 1999; LeClaire, Hunt et al. 2002; Hu, Omoe et al. 
2003). The present dogma in immune protection against S. aureus is that a 
protective immune response is possible when a recombinant antigen is used, but 
during natural infection no protective antibody response is generated. This view can 
be challenged. Dryla (Dryla, Prustomersky et al. 2005) showed that high-titer 
antistaphylococcal antibodies are stable for years in healthy individuals, and 
provided evidence that these antibodies are functional on the basis of 
opsonophagocytic and neutralizing activity. In a study of paediatric patients 
infected with CA S. aureus (Brown, Bowden et al. 2009), it was demonstrated that 
patients infected with Panton-Valentin leucocidin (PVL)-positive strains developed 
a dominant IgG anti-PVL antibody response. This response was attributable to a 
specific humoral response against the antigen, and it was at the expense of antibody 
response to other virulence factors. 
 
Active immunization in clinical trials 
Most S. aureus strains are encapsulated, with capsular polysaccharides serotype 5 
(CP5) or serotype 8 (CP8) being the most common among 11 serotypes. Fattom 
(Fattom, Schneerson et al. 1993) conjugated CP5 and CP8 to protein (recombinant 
Pseudomonas aeruginosa exotoxoid A). The vaccines were highly immunogenic in 
mice and humans, and antibodies elicited by immunization opsonised encapsulated 
S. aureus for phagocytosis. 
 
A combined bivalent vaccine, both CP5 and CP8, was tested in haemodialysis 
patients to prevent bacteraemia 2002 (Shinefield, Black et al. 2002). At week 54 
after vaccination the vaccine efficacy was only 26%, which was not statistically 
significant, but when earlier time periods were analyzed, the vaccine was found to 
significantly reduce the incidence of bacteraemia between weeks 3 and 40. A 
subsequent confirmatory clinical trial in 3,600 haemodialysis patients did not repeat 
the positive results, and the further development of this vaccine ceased (Schaffer 
and Lee 2009). The failure of the vaccine may, in part, have been due to the 
immunocompromised status of the patients. 
 
Passive immunization in clinical trials 
S aureus adheres to host molecules through surface protein adhesins, also referred 
to as microbial surface components recognizing adhesive matrix molecules, or 
MSCRAMMs. Clumping factor A (ClfA) mediates binding to fibrinogen 
(McDevitt, Francois et al. 1994), biomaterial surfaces (Vaudaux, Francois et al. 
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1995), blood clots, damaged endothelial surfaces (Moreillon, Entenza et al. 1995), 
and platelets (Sullam, Bayer et al. 1996). Protective antibodies were demonstrated 
in experimental models (Josefsson, Hartford et al. 2001), and the Inhibitex 
company developed a pooled immunoglobulin preparation from donors with high 
antibody titers against staphylococcal adhesins that bind fibrinogen and fibrin. A 
phase 3 double-blind, placebo-controlled study was conducted in 1,983 infants, 
aiming to reduce bacteraemia (DeJonge, Burchfield et al. 2007). There were no 
differences in the two groups, 6% bacteraemia in the study group and 5% in the 
control group. The results were disappointing, because the immunoglobulin 
product, although selected for its antibodies to Clf A, probably contained antibodies 
to many other staphylococcal antigens, and so could be considered multicomponent 
passive immunotherapy. The product was not elicited by immunization but by 
natural exposure to S. aureus, and therefor the antibodies might have recognized the 
wrong Clf A epitopes, or may have been of low affinity. 
 
Antigens 
Numerous virulence factors are described in S. aureus, cellwallbound factors, 
toxins and enzymes (Table 1). 
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Table 1. Staphylococcus aureus Extracellular Factors Involved in Pathogenesis, and Response to Global Regulatory 
Elements during Bacterial Growth 
     Action of Regulatory 
Genes† 
Gene Location Product Activity/Function Timing* agr sae rot sarA 
Surface Proteins       
spa Chromosome Protein A Anti-immune, 
antiphagocytosis 
exp  ≠ 
 
+  
cna PT islet§ Collagen BP Collagen binding p-exp 0    
fnbA Chromosome Fibronectin BPA Fibronectin binding exp    + 
fnbB Chromosome Fibronectin BPB Fibronectin binding exp    + 
clfA Chromosome Clumping factor A Fibrinogen binding exp 0    
clfB Chromosome Clumping factor B 
Lactoferrin BP 
Fibrinogen binding 
Lactoferrin binding 
exp 0  + 0 
Capsular Polysaccharides       
cap5 Chromosome CP5 Antiphagocytosis? p-exp +   + 
cap8 Chromosome CP8 Antiphagocytosis? p-exp +    
Cytotoxins       
hla Chromosome α-Hemolysin Hemolysin, cytotoxin p-exp + + + ≠ 
hlb Chromosome β-Hemolysin Hemolysin, cytotoxin p-exp + + + ≠ 
hld Chromosome δ-Hemolysin Hemolysin, cytotoxin xp + 0  + 
hlg Chromosome γ- Hemolysin Hemolysin, cytotoxin p-exp +  + ≠ 
lukS/F PVL phage PVL leukocidin Leukolysin p-exp +  +  
Superantigens       
sea Bacteriophage Enterotoxin A Food poisoning, TSS xp 0    
seb SaPI3¶ Enterotoxin B Food poisoning, TSS p-exp +   ≠ 
sec SaPI4¶ Enterotoxin C Food poisoning, TSS p-exp +    
sed Plasmid Enterotoxin D Food poisoning, TSS p-exp +    
eta ETA phage Exfoliatin A Scalded skin syndrome p-exp +    
etb Plasmid Exfoliatin B Scalded skin syndrome p-exp +    
tst SaPI1, 2, bov1 Toxic shock toxin-1 Toxic shock syndrome p-exp +   + 
Enzymes       
spIA-F Chromosome Serine protease-like Putative protease  +  +  
ssp Chromosome V8 protease Spreading factor p-exp + 0  + 
aur  Metalloprotease 
(aureolysin) 
Processing enzyme? p-exp +   + 
sspB  Cysteine protease Processing enzyme?  +  +  
scp  Staphopain 
(protease II) 
Spreading, nutrition p-exp +   + 
geh Chromosome Glycerol ester hydrolase Spreading, nutrition p-exp + 0 + ≠ 
lip  Lipase (butyryl esterase) Spreading, nutrition p-exp + 0  ≠ 
fme Chromosome FAME Fatty acid esterification p-exp +   ≠ 
plc  PI-phospholipase C  p-exp +    
nuc Chromosome Nuclease Nutrition p-exp + +   
hys Chromosome Hyaluronidase Spreading factor xp ≠    
coa Chromosome Coagulase Clotting, clot digestion exp  + + + 
sak Bacteriophage Staphylokinase Plasminogen activator p-exp + 0   
†agr, accessory gene regulator; sae, Staphylococcus aureus exoproteins; rot, repressor of toxins; sarA, Staphylococcus accessory 
regulator. 
*Timing: xp, throughout exponential phase; exp, early exponential phase only; p-exp, postexponential phase; 0, no effect of gene on 
expression;+, upregulated; -, downregulated. 
≠Controversial. 
§PT islet, pathogenic islet. 
¶SaPI, Staphylococcus aureus pathogenic island. 
BP, binding protein; ETA, exfoliative toxin A; PVL, Panton-Valentine; TSS, toxic shock syndrome. 
Adapted from Cheung AL, Projan SJ, Gresham H. The genomic aspect of virulence, sepsis, and resistance to killing mechanisms in 
Staphylococcus aureus. Curr Infect Dis Rep. 2002;4:400-410, and Novick RP. Autoinduction and signal transduction in the regulation 
of staphylococcal virulence. Mol Microbiol. 2003; 48:1429-1449. 
With permission from Elsevier Company: The online version of 6th edition of Mandell, Douglas and Bennett's "Practice and principle 
of Infectious Disease" 2009. 
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Teichoic acid TA 
Teichoic acids are cellwall components which are covalently linked to 
peptidoglycan. They consist of ribitol residues joined through phoshpodiester 
linkages and substituted with glucose and/or N-acetylamino sugar, and/or 
sometimes D-alanine. The antibody test is the most thoroughly investigated 
serological test, and probably the most frequently used one. Antibody rise is seen in 
serious staphylococcal infections (Julander, Granstrom et al. 1983). Weidenmaier 
(Weidenmaier, Kokai-Kun et al. 2004) showed that teichoic acid plays a role in the 
nasal colonization of. S aureus. 
 
Alpha toxin AT 
AT is a pore-forming, secreted toxin with haemolytic activity and broad specificity. 
Most clinical isolates are reported to produce AT. Already more than a century ago, 
antibodies against staphylolysin were demonstrated in healthy individuals and in 
patients with staphylococcal infections (Neisser 1901). As with teichoic acid, 
antibody rise is seen in serious staphylococcal infections (Julander, Granstrom et al. 
1983). In an animal model vaccination against AT protected against pneumonia 
(Bubeck Wardenburg and Schneewind 2008). Ruotsalainen (Ruotsalainen, Karden-
Lilja et al. 2008) found an elevated initial ASTA titer significantly more often 
among injection drug users without endocarditis than those with endocarditis (44% 
vs. 6%). A toxoid prepared from AT, but also from other toxins, has been in use in 
Russia for several decades for production of a hyperimmune plasma product (Kelly 
2000). Healthy individuals were vaccinated with the toxoid and 2-3 L of immune 
plasma was collected from each donor. The product was used in many clinical 
settings, but there exist no controlled studies and the scientific literature are almost 
entirely in the Russian language. 
 
Lipase 
S. aureus is one of the few bacterial species that produces an extracellular lipase. 
Strains isolated from deep or subcutaneous infections show a higher lipase 
production than strains isolated from superficial locations, and in addition to the 
nutritive function of the enzyme, it is believed to be an invasive factor (Rollof, 
Hedstrom et al. 1987). Antibody response is seen in bacteraemia (Christensson, 
Fehrenbach et al. 1985; Colque-Navarro, Soderquist et al. 1998). 
 
Extracellular fibrinogen binding protein Efb 
Extracellular fibrinogen binding protein is one of several fibrinogen binding 
proteins produced by S. aureus. Efb binds to both fibrinogen and platelets and 
inhibits platelet function both in vitro and in vivo, as well as contributing to 
virulence in wound infections. An antibody response is seen in patients with 
bacteraemia (Colque-Navarro, Palma et al. 2000). Efb-negative mutants have 
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shown less virulence in a murine model of wound infection (Palma, Nozohoor et al. 
1996). Antibodies generated in response to immunization with Efb protected 
against the effects of Efb in a foreign-body-associated wound infection model in 
mice (Shannon, Uekotter et al. 2006). In the same study, human IgG against Efb 
was prepared from commercial IgG pools; however the enriched monospecific 
human anti-Efb was unable to neutralize Efb. 
 
Clumping factor A ClfA 
Clumping factor A is a cellbound fibrogen-binding protein, and the gene for CflA is 
found in the vast majority of S. aureus strains (Peacock, Moore et al. 2002). The 
biological role of ClfA has been evaluated in experimental animal models of septic 
arthritis (Josefsson, Hartford et al. 2001) and endocarditis (Moreillon, Entenza et al. 
1995), with mutants exhibiting reduced virulence. A monoclonal antibody has 
shown protective properties in a murine sepsis model (Hall, Domanski et al. 2003). 
As with Efb, an antibody response is documented in patient with bacteraemia 
(Colque-Navarro, Palma et al. 2000). 
 
Clumping factor B ClfB 
Clumping factor B is a fibrinogen-binding protein, but it also binds to type I 
cytokeratin of squamous epithelial cells in animals and humans (Wertheim, Walsh 
et al. 2008). There are conflicting results concerning the antibody responses: 
Wertheim reported higher titers in carriers of S. aureus in the nose, than in non-
carriers, Dryla (Dryla, Prustomersky et al. 2005) demonstrated the opposite. 
 
Bone sialoprotein binding protein Bsp 
Bone sialoprotein-binding protein is a cellwall glycoprotein that binds bone 
sialoprotein. It has been shown in several studies that patients with S. aureus caused 
osteomyelitis mount a specific antibody response to Bsp (Ryden, Yacoub et al. 
1989; Persson, Johansson et al. 2009). 
 
Extracellular adherence protein Eap 
This protein, also called the major histocompatibility class II analogue protein, 
Map, mediates adherence to a variety of extracellular matrix components such as 
vitronectin, fibronectin, fibrinogen, and collagen, and enhances internalisation into 
eukaryotic cells (Joost, Blass et al. 2009). It reduces neutrophil recruitment and T 
cell proliferation and response. S. aureus mutants have shown reduced virulence in 
abscess and wound models (Joost, Blass et al. 2009). Human anti-Eap antibodies 
prepared from polyspecific immunoglobulin G (IgG) were found to block the 
immunomodulatory effects of Eap (Haggar, Shannon et al. 2005). 
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Staphylococcal Enterotoxin A SEA 
Staphylococcal enterotoxin A belong to a family of heat-resistent toxins, also 
resistant to acid and basic pH. SEA was the first toxin identified in staphylococcal 
food poisoning (Chu, Thadhani et al. 1966). It also has superantigeinic properties as 
a potent T cell mitogen. Most staphylococcal superantigens are encoded by 
accessory genetic elements, and these mobile elements are not uniformly 
distributed among clinical isolates. 
Toxic Shock Toxin TST 
TST belongs to the same family of pyrogenic toxin superantigens, as 
staphylococcal enterotoxins (SE). TST is unique in its ability to cross mucosal 
surfaces. The toxin is a potent T-cell activator and is found in patients with Toxic 
Shock Syndrome (TSS). Patients with recurrent TSS are unable to produce 
antibodies against TST. In patients with bacteraemia, an antibody response was 
noted in 92% of patients infected with a S. aureus isolate producing TST or SEA-
SED (Kanclerski, Soderquist et al. 1996). However, 10% of patients infected with 
isolates with no toxin production reacted with an antibody response. 
 
TST has been implicated in arthritis (Schwab, Brown et al. 1993), and a potential 
role is suggested in Kawasaki disease (Matsubara and Fukaya 2007).  
 
Staphylococcal Scalded Skin Toxin SSS 
SSS toxin consists of two serotypes, exfoliatin A and B, which cause bullous 
impetigo, and the generalized counterpart, scalded skin syndrome. These skin 
diseases mainly affect children, but also immunocompromised adults. One 
proposed explanation is immunologic immaturity with low antibodies titers 
(Ladhani 2003). It has been a controversy if the toxin possesses superantigenic 
properties. Current evidence suggests that the exfoliate toxins exert superantigenic 
activity because they induce selective polyclonal expansion of T-cells restricted to 
certain Vβs (variable part of the β-chain in the T-cell receptor). 
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Carriers of S. aureus 
Healthy individuals can be carriers of S. aureus in the anterior nasal region. The 
throat and the perineum are also important reservoirs. It is believed that 
approximately 20% of the population are persistent carriers, 30% are intermittent 
carriers, and 50% are non-carriers (Wertheim 2005). The prevalence of nasal 
carriage varies, however, and is higher in young children, men, white people, 
hospitalized patients, and a number of patient groups, including patients with 
diabetes mellitus, patients undergoing haemodialysis, or chronic ambulatory 
peritoneal dialysis, patients with S. aureus skin infection, and HIV-infected patients 
(van Belkum, Melles et al. 2009). Several bacterial carriage determinants have been 
studied, such as teichoic acid, lipoteichoic acid, fibronectin-binding protein, and 
clumping factor B. Eradication of S. aureus from the nose has proved to be 
effective in reducing the incidence of staphylococcal infection (Kalmeijer, 
Coertjens et al. 2002; Perl, Cullen et al. 2002). Carriers have increased risk of 
nosocomial bacteraemia as compared with non-carriers, but their outcome is better 
(Wertheim, Vos et al. 2004). Holtfreter (Holtfreter, Roschack et al. 2006) reported 
that carriers neutralize superantigens by antibodies specific to their colonizing 
strain. Persistent carriers have higher antibody titers than non-carriers against TST, 
SEA, ClfA and ClfB (Verkaik, de Vogel et al. 2009). Recently, van Belkum (van 
Belkum, Verkaik et al. 2009) showed that there is no difference between non-
carriers and intermittent carriers regarding nasal elimination kinetics and antibody 
profile, and proposed just two categories, carriers and non-carriers. 
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Aims 
 
Our investigation was undertaken with the following aims: 
 
• To describe, prospectively, the epidemiology of ISA in a well-defined 
population with low frequency of MRSA colonization and to characterize 
and quantitative estimate the risk factors, and to characterize the clinical 
presentation of ISA. 
 
• To determine the mortality, recurrence rate, and residuals symptoms of ISA 
in a prospective, population-based manner. 
 
• To examine the impact of virulence regulator agr on disease presentation. 
 
• To investigate the humoral immune response towards S. aureus in a well-
characterized patient cohort with ISA. 
 
• To evaluate the humoral immune response towards S. aureus in a cohort of 
healthy individuals, and to estimate the impact of carrier-state of S. aureus on 
antibody production. 
 27 
Materials and Methods 
Patients 
Every individual, irrespective of age, who resided in the health care region of 
Skaraborg Hospital and who had an ISA between 1 March 2003 and 28 February 
2005 were prospectively included in the study. The health care region of Skaraborg 
Hospital consists mainly of small towns and rural areas. Patients requiring 
transplantation and thoracic/neurosurgical surgery are transferred out of the region 
and were therefore not included, unless diagnosed in the county. Patients with 
recurrences were included several times. Relapses in the follow-up period until 1 
September 2005, were also considered (1 episode). 
 
During the two-year study, 168 patients had at least one ISA. Eight patients were 
excluded. Five were considered as insignificant culture results (contaminants) and 3 
were excluded because they lived outside the catchment area. Three patients were 
missed for inclusion. A total of 170 episodes were registered, all episodes were 
included in the analysis. The median age of the patients was 72 years (range 
newborn to 97 years), and the mean age was 65 years. Men dominated, 58%, versus 
42% women. Thirteen children (age ≤ 18 years) were registered with ISA. The 
median duration of symptoms before admission was two days (range 0-193 days). 
 
The antibody response was determined in three samples, at the time of diagnosis 
(n=96), after completed antibiotic treatment (n=71), and in convalescence, one 
month after the end of treatment (n=51). The median time from start of symptoms 
to sample one was 6 days, with the mode time 4 days. 
 
Controls 
Healthy individuals attending an outpatient vaccination clinic at Skaraborg Hospital 
were asked to join the study group. They had to fill in a questionnaire, determining 
that they had no chronic illnesses, had not been cared for in hospital the last 12 
months, and did not have a joint prosthesis. From 115 healthy individuals one 
serum sample was obtained. They were screened once for nasal carriage of S. 
aureus, and 25 (22%) were positive. The median age was 70 y (mean 61 y), with 
56% men. 
 
In paper IV, 36 samples of younger blood donors were added, in order to 
compensate the skewed age distribution of the individuals. 
Among the compound group, the gender distribution was 90 men and 60 women 
(missing information about sex in one individual), with age averages 56 and 50 y. 
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Study protocol 
The Clinical Microbiological Laboratory, Unilabs Skövde, which handles all the 
routine bacterial specimens from the area, carried out surveillance for ISA. A total 
of 197 invasive isolates of Staphylococcus aureus were obtained from the 157 
patients with a total of 170 episodes. All isolates were of MSSA. In 141 episodes 
the isolates were from blood. 
 
Other isolates were from synovial fluid in 19 episodes, diverse sites (deep-seated 
abscesses, bone, and pleural fluid) in 15 episodes and from cerebrospinal fluid in 2 
episodes. There were no outbreaks of S. aureus infections reported during the study 
period. 
 
The study physician in charge was notified and included the patients who fulfilled 
the inclusion criteria. Consent was obtained from the patients or their relatives after 
written and oral information. The Ethics Committee at Sahlgrenska Academy of 
Gothenburg University approved of the study. In the protocol we registered medical 
history, clinical findings and laboratory results at the time of diagnosis. A blood 
sample was drawn for serology. At the end of antibiotic therapy we conducted a 
clinical examination if the patient was still in hospital or was able to attend the 
outpatient clinic, drew a blood sample for serology, and reviewed clinical data. We 
repeated the procedure 1 month after the end of antibiotic therapy. 
 
Definitions 
ISA 
ISA was defined by the isolation of S. aureus from an otherwise sterile site, i.e. 
blood, synovial fluid, cerebrospinal fluid, pleural fluid, bronchoalveolar lavage, or 
from a sterile taken deep-seated abscess. Bacteraemia was defined as the presence 
of at least one positive blood culture for SA. All positive cultures were categorized 
as true or contaminant by evaluating the clinical history, physical findings, clinical 
course, and response to treatment. Community-acquired infections were defined as 
those associated with the first positive culture within 48 h of admission. Health 
care-related infections were defined as those occurring in patients residing in a 
nursing home or receiving health care at home. If the first positive culture was 
obtained later then 48 h after admission, the case was classified as nosocomial. A 
diagnosis was assigned on the basis of clinical, radiological and microbiological 
information. 
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Endocarditis 
Endocarditis was diagnosed using the Duke criteria (Durack, Lukes et al. 1994). 
Ten patients were diagnosed with endocarditis (7% of the bacteraemia cases, 6 
definitive and 4 possible). 
 
Severe sepsis 
Severe sepsis was defined according to the 2001 SCCM/ESICM/ACCP/ATS/SIS 
International Sepsis Definitions Conference (Levy, Fink et al. 2003). All patients 
with sepsis, together with hypotension, hypoperfusion or organ dysfunction, were 
classified as severe sepsis. 
 
In 51 (30%) of the episodes, severe sepsis occurred. 
 
Complicated bacteraemia 
Complicated bacteraemia was considered if bacteraemia presented with a 
secondary focus, such as endocarditis, spondylitis, osteomyelitis, arthritis, deep-
seated abscess or pneumonia. Line-associated infections were not registered as 
complicated bacteraemia, nor was urinary tract infection, soft-tissue infection with 
no metastatic seeding or bacteraemia without focus. 
 
In 55 (32%) episodes, complicated bacteraemia occurred, representing 40% of the 
bacteraemia cases. 
Recurrence 
Recurrence was defined as a new episode of ISA occurring more than 4 weeks after 
the time of the first diagnosis and after the antibiotic therapy was complete. Twelve 
patients had a second episode of illness. One patient suffered two recurrences, i.e. a 
total of 13 relapses. The median time for recurrences was 76 days, with a minimum 
of 29 days, a maximum of 422 days, and an interquartile range of 42-274 days. The 
median follow-up time was 347 days. 
 
Residual symptoms 
Residual symptoms were evaluated one month after the antibiotic therapy was 
completed, either by clinical examination in the hospital or at the outpatient clinic, 
or by a telephone call with the patient or an appropriate caregiver. Forty-four (34%) 
patients reported sequelae. 
 
 30 
Adequate empirical antibiotic therapy 
Adequate empirical antibiotic therapy was defined in cases of bacteremia as 
parenteral antibiotics to which the bacterium was susceptible. In non-bacteremia 
cases adequate empirical therapy was defined as parenteral or oral antibiotic to 
which the bacteria was susceptible. Examples of non-adequate antibiotics were 
ceftazidim, penicillin G, ciprofloxacin, trimethoprim/sulfamethoxazol. 
 
Fifteen (10%) patients received non-adequate empirical antibiotic therapy, and 18 
(13%) were not treated with antibiotics within 24 h of admission or start of illness 
in hospital. 
 
Antigens 
Ribitol teichoic acid (TA) and Alpha-toxin (AT) were purchased from PhPlate AB 
(Stockholm, Sweden). Enterotoxin A (SEA), Toxic Shock Syndrome Toxin 1 
(TST), and Scalded Skin Syndrome toxin (SSS) were purchased from Toxin 
Technology (Florida, USA). Lipase was kindly supplied by S. Tyski (Medical 
University of Warzaw, Poland). Clumping factor A (Clf A), Clumping factor B (Clf 
B), Extracellular fibrinogen binding protein (Efb), and Extracellular adherence 
protein (Eap) by J.I. Flock (Karolinska Institute, Stockholm). Bone sialoprotein 
protein (Bbp) by C. Rydén (Uppsala University). 
 
ELISA 
The antigen coating concentration was 0.6 μg/ml for Efb, 1 µg/ml for TA, ClfA, 
ClfB, SEA, TST, SSS, and Eap, 2 µg/ml for Clf, 3.5 µg/ml for AT, and 4 μg/ml for 
Bbp. Serum samples were diluted twofold in PBS-T (1/250 to 1/2000) in AT, Clf, 
Efb, TST and SSS assays and (1/2500 to 1/20000) in TA and lipase assays. The 
reference serum consisted of pooled sera from six patients with confirmed sepsis 
(Colque-Navarro, Palma et al. 2000). The four dilutions, controls and reference 
serum were applied and incubated for 1 h at 37°C. Thereafter alkaline phosphatase 
conjugated to goat anti-human antibodies (Sigma Chemical Co., St. Louis, Mo.) 
diluted 1/3000 in PBS-T was added, and incubation was continued for 2 h at 37°C. 
Finally, the enzymatic reaction was measured at 405 nm in a Titertek Multiscan 
microplate reader (Flow Laboratories, Irvine, Scotland) after approximately 20 min 
incubation. 
Interpretations of ELISA results 
The absorbance values were transformed into arbitrary units by using the reference 
line units calculation method (Reizenstein, Hallander et al. 1995). The dilution 
curve of each sample was made parallel to that of the reference serum, after which 
the two curves were compared. The reference serum was given the value of 1,000 
(arbitrary) units for all antigens and the patient serum antibody levels were 
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expressed in these units. This means that the unit levels obtained cannot be directly 
compared between antigens, since the absolute values are dependent upon those of 
the reference serum. 
 
The upper limits for “normal antibody levels” were established as the upper 95th 
percentiles of the levels found in the healthy individuals. Levels above this cut-off 
level were designated as high levels. A significant rise of antibodies was defined as 
a 50% increase between two samples and a significant decrease of antibodies was 
defined as a 50% decrease. A patient was considered to show positive serology 
when a high level in at least one serum sample from the patients with at least two 
samples and/or a significant increase/decrease of antibody levels was noted. Some 
sera were designated as low levels. The limits for these levels varied from 50 to 150 
units for the different antigens as determined by the reproducibility of the 
respective test. 
Typing of agr groups by PCR 
To screen the isolates for agr groups I, II, II, and IV, primers of Peacock (Peacock, 
Moore et al. 2002) were used with Polymerase Chain reaction (PCR). Each strain 
was analysed using all primer pairs. Sequenced strains, used as positive controls, 
were included in each run. The final concentration of the PCR mixture was 5 ng 
DNA template, 1x reaction buffer, 2 mM Cl2, 100 pmol of forward and reverse 
primers, 0.2 mM deoxynucleoside triphosphate mix and 2.5 U of Taq polymerase 
(New England BioLabs). The PCR thermal cycling program was initial 
denaturation of 94°C for 5min, 35 cycles of 94° for 1 min, 55.8°C for 1min, and 
72°C for 1min, and a final extension of 72°C for 10 min. 
 
Sixty-two (37%) of the episodes belonged to agr group I (one isolate in one episode 
could not be typed), 42 (25%) belonged to agr II, 56 (33%) to agr III, and 9 (5%) 
to agr IV. 
 
PCR tst gene 
The presence of the tst1 gene in S. aureus strains were analyzed by PCR using the 
following primers (5’?3’): tst1 forward: ATC GTA AGC CCT TTG TTG CTT G; 
and tst1 reverse: CTT TGA TAT GTG GAT CCG TCA TTC. The final 
concentration of the PCR mixture was same as for agr group typing except that 20 
pmol of forward and reverse primers were used in each PCR reaction. The PCR 
thermal cycling program was an initial denaturation of 94°C for 5 min, 35 cycles of 
94°C for 1 min, 63°C for 1 min, and 72°C for 1 min, and a final extension of 72°C 
for 10 min. 
 
One hundred sixty-seven isolates were evaluated, 29 (17%) were positive for the tst 
gene. 
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Typing by PFGE 
Genome typing by pulse field gel electrophoresis was performed in principle as 
described by Tenover (Tenover, Arbeit et al. 1994).Visual interpretation of the 
banding pattern according to cited criteria was made, resulting in a cut-off of 75% 
in the dendrograms generated, above which strains were considered to be closely 
related. Eighty-six isolates could be evaluated with PFGE, 33 (38%) belonged to 
group 1, 37 (43%) to group 2, 9 (10%) to group 3, and 7 (8%) to group 4. 
 
Production of alpha-haemolysin 
Screening for alpha-haemolysin production was carried out on nutrient agar plates 
(8 mm high) containing rabbit erythrocytes. The bacterial colonies on the agar 
plates after incubation at 37°C overnight had a diameter < 3 mm. The diameter of 
the zone of haemolysis (mm), was determined. 
Data sources 
Regional data that account for all patients in the health care region of Skaraborg 
were used, and the study population was 255,109 on 31 December 2004. The 
Swedish Register of Uraemia Care provided the number of haemodialysis and 
peritoneal dialysis patients, 108 and 22 respectively, on 1 March 2004. The 
expected number of patients with rheumatoid arthritis aged over 18 years, 997, was 
estimated from a survey in Sweden (Simonsson, Bergman et al. 1999). The regional 
Diabetes Register provided the number of patients with diabetes mellitus: 9,912, on 
1 January 2004. The number of cancer patients, i.e. the prevalence of patients living 
with a cancer diagnosis diagnosed during the last 15 years, 8,554, was supplied by 
the regional Oncology Centre. 
Statistics 
Data were analysed using SPSS (version 11.5 and version 15.0), Excel 97, 
GraphPad Prism, and PhPWin. Medians with range were used to describe age; 
means and medians were used to describe duration. Differences in proportions were 
compared using Fisher’s exact test or Pearson Chi square test, and quantitative 
variables were analysed with Student’s t-test. The non-parametric Mann-Whitney 
test was used for variables that were not normally distributed.  
Antibody levels were presented as by descriptive statistics as medians and quartiles 
and illustrated by box-plots. Comparisons between groups were analyzed with 
Mann-Whitney U nonparametric test regarding quantitative variables. Comparisons 
with obtained and expected numbers of individuals showing high or low antibody 
levels were performed with Chi square test. For comparisons of levels between 
individuals the unit values were normalized into quotients of their respective mean 
values, upon which pairwise correlation coefficients and clustering was performed 
according to the UPGMA method by the PhPWin software. 
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Statisticians Anders Odén and Salmir Nasic were consulted when calculating 95% 
confidence interval for relative risk. Confidence intervals for odds ratio, OR, were 
calculated by use of logistic regression. Variables found to be significant in a 
univariate analysis of mortality were included in the multivariable logistic 
regression analysis. Two variables (At least one previous episode and Age) were 
included for other reasons than the significant contribution to the prediction of 
death within 28 days. One variable (Bacteraemia) found to be significant in the 
univariate analysis was not included in the multivariable logistic regression analysis 
for technical reasons (0 deaths in a category variable). Based on the significant 
variables in the logistic regression analysis plus the variable Age, a compound 
quantitative predictor of probability of death was constructed and evaluated in a 1-
Specificity -Sensitivity curve ( ROC (Relative Operating Characteristics)-curve). 
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Results and Discussion 
 
Incidence, risk factors for acquisition, clinical presentation 
(Paper I, II) 
Hitherto, the incidence of ISA or S. aureus bacteraemia has not been described in 
Sweden The annual incidence of ISA in our study among residents of Skaraborg 
was 31.4 cases/100,000 population (not including relapses), 33.9 cases with 
relapses included.. The incidence of ISA is higher than that of pneumococcal 
disease with 10.3 cases/100,000/y reported in a retrospective study from a nearby 
region by Dahl (Dahl, Trollfors et al. 2001). Invasive pneumococcal disease is a 
mandatory reportable disease in Sweden, and the Swedish Institute for Disease 
Control (SMI) report an incidence of 19.3/100,000 for y 2008 (SMI 2009). Dahl 
(Dahl, Tessin et al. 2003) reported an incidence of invasive group B streptococcal 
infection to be 2.4/ 100,000/y. The incidence of ISA is 5-20 fold higher than that of 
invasive group A streptococcal or group B streptococcal infections as reported in 
studies from other regions (Davies, McGeer et al. 1996; Farley, Harvey et al. 1993). 
Our reported incidence is slightly higher than that in the prospective, population-
based study of ISA in Canada by (Laupland, Church et al. 2003) with an incidence 
of 28.4 cases/100,000/y, recurrences not included in the analysis. 
 
We found only 13 children with ISA, giving an incidence of 10.4 cases/100,000/y. 
Hill (Hill, Wong et al. 2001) reported a higher figure (16.9/100,000/y) for 
bacteraemia in children. 
 
Morin 2001 (Morin and Hadler 2001) reported, in a population-based study 
although with a retrospective design, an incidence of 35.4 cases/100,000/y, only 
including bacteraemia cases. Our incidence of S. aureus bacteraemia cases was 
27.6/100,000/y, and presumably the rates would be higher in other areas with 
higher prevalence of risk groups. Approximations based on data reported to EARSS 
claim a figure of 2,195 cases of bacteraemia (Melander, Burman et al. 2007) i.e. 
24.3/100,000/y in Sweden. Laupland (Laupland, Ross et al. 2008) reported an 
annual rate of S. aureus bacteraemia on 19.7/100,000. Jensen (Jensen, Wachmann 
et al. 1999) estimated an incidence of 30/100,000/y, but this was a case-control 
study of S. aureus bacteraemia acquired in hospitals. 
 
We documented 25 episodes of arthritis, with an annual rate of 4.7/100,000. 
Weitoft (Weitoft and Makitalo 1999) reported an incidence of 4.1/100,000/y of all 
bacterial arthritis in another region of Sweden, where children were not included. 
Kaandorp (Kaandorp, Krijnen et al. 1997) observed a rate of 2.5/100,000/y for 
septic arthritis attributable to S. aureus. 
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In summary, our results show that S. aureus is a leading bacterial pathogen in 
invasive diseases, and that figures based on non-mandatory surveillance are not 
reliable. 
 
We identified known risk groups for ISA, but in a quantitative manner, with 
haemodialysis and peritoneal dialysis patients as the groups with highest relative 
risk. Laupland (Laupland, Church et al. 2003) estimated the quantitative risk for 
ISA, but our prevalence data for risk groups seem to be more reliable. 
 
The spectrum of clinical presentation of ISA is wide, and a small proportion, 18% 
of the episodes, were initially cared for at the Department of Infectious Diseases. 
One quarter of the patients had no history of fever at presentation, even among 
bacteraemia cases. Several cases of bacteraemia showed a modest inflammatory 
response in relation to several parameters: 31% with a normal white blood cell 
count (<10x109 /l), and 29% with a CRP(C-reactive protein) value below 100mg/l. 
In non-bacteraemia episodes, only 45% reported a history of fever. This prompts a 
high degree of clinical suspicion of ISA, not to fail to detect a substantial number of 
infections. Children had significantly higher fever at presentation than adults. 
 
The most common diagnoses, irrespective of primary or secondary focus diagnosis, 
were soft tissue infection, bacteraemia without focus, infections of intravenous 
lines, and joint/bone infections (Table 2), as reported by others (Laupland, Church 
et al. 2003). Thirty-two percent of the episodes were classified as complicated 
bacteraemia, and 30% were classified as severe sepsis. In children, the most 
common diagnosis was line-associated infection and osteomyelitis, the same as 
observed by (Hill, Wong et al. 2001). 
 36 
 
Table 2. 
Primary diagnosis in 170 episodes with invasive Staphylcoccus aureus 
Diagnosis n % 
(n=170)
Annual 
incidence 
(per 100 000) 
Age 
Median  
(range) years
Community-acquired 
infections 
n (%) 
Health-
related 
infections 
n (%) 
Nosocomial 
infections 
n (%) 
pb 
Soft tissue infection 47 27 9.2 74 (4-93) 25 (53) 10 (21) 11 (23.4) n.s 
Bacteraemia without focus 32 19 6.5 75 (36-97) 14 (44) 6 (19) 12 (36.4) n.s 
Arthritis 25 15 4.7 67 (15-90) 19 (76) 2 (8) 4 (16.7) 0.004 
Line associated infection 24 14 4.9 68 (0-89) 3 (12) 5 (21) 16 (64) 0.001 
Osteomyelitis other than 
vertebral 
16 9 2.9 59 (10-89) 12 (75) 3 (19) 1 (6.7) 0.031 
Endovascular infection 12 7 2.4 78 (38-95) 6 (50) 2 (17) 4 (33.3) n.s. 
Urinary tract infection 10 6 1.9 70 (37-89) 6 (60) 2 (20) 2 (22.2) n.s. 
Respiratory infection 9 5 1.9 73 (0-94) 2 (22) 2 (22) 5 (55.6) n.s. 
Vertebral osteomyelitis 8 5 1.6 70 (53-95) 7 (88) 1 (12) 0 (0) 0.027 
Intraabdominal infection 7 4 1.4 68 (18-87) 4 (57) 1 (14) 2 (28.6) n.s. 
Meningitis 2 1 0.4 53 (50-55) 1 (50) 1 (50) 0 (0) n.s. 
Other (epidural abscess) 1 1 0.4 60 1 (100) 0 (0) 1 (100) n.s. 
Sum 193a        
a Patients could have several diagnosis 
b Community-acquired infections versus health-related infections and nosocomial infections 
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Mortality (Paper II) 
In the course of the first 28 days, 30 (19.1%) patients died, and during the total 
follow-up time, 41 patients (26.1%) died, giving an annual population mortality due 
to ISA of 5.9/100,000. This is a higher figure than Laupland (Laupland, Ross et al. 
2008) described from the Calgary Health Region in Canada: he reported an annual 
mortality during 2000-2006 of between 4 and 5/100,000, with the exception of 
2005, when reaching nearly 6/100,000. This was in spite of the substantial number 
of cases with MRSA with known higher mortality, and with a seemingly higher 
prevalence of risk groups. It is important not to translate incidence- and mortality 
figures for ISA from different catchement areas uncritically. 
 
Among specific diagnoses we found the highest mortality in patients with 
bacteraemia without known source, patients with respiratory infections, and 
patients with endovascular infections, which is in agreement with the findings of 
others (Mylotte and Tayara 2000). Only 40 of the patients in our study were 
examined with either transthoracic or transoesophageal echocardiography (34% of 
the bacteraemia cases), so we may have underestimated the rate of endocarditis. 
Higher rates of endocarditis than ours, 6%, have been reported by Chang (Chang, 
MacDonald et al. 2003), 13%, and echocardiography has been proposed as a 
standard examination method in the early evaluation of patients with SAB (Fowler, 
Li et al. 1997; Rosen, Fowler et al. 1999).  
We could not discern any difference in mortality between cases with community-
acquired infections, cases with health care-associated infections, and cases with 
nosocomial infections. Age over 65 years and concomitant heart disease are 
variables associated with increased mortality (Table 3), in accordance with other 
studies (Laupland, Church et al. 2003). We could not find any treatment 
characteristic that affects mortality, apart from the surprising result that patients 
with adequate empirical antibiotic therapy had higher mortality. Laupland found 
that patients treated with empirical antibiotics within 8 hours had a higher mortality 
rate. The explanation may be that patients with a poorer prognosis present with 
more severe clinical findings and are more likely to be treated empirically with 
broad-spectrum antibiotics. Several studies have documented the beneficial effects 
of early antibiotic therapy (Leibovici, Shraga et al. 1998; Lodise, McKinnon et al. 
2003). Lodise demonstrated that delaying therapy for >45 h substantially increased 
the risk of infection-related mortality in patients with hospital-acquired SAB. Like 
ours, others studies (Kaech, Elzi et al. 2006) have failed to demonstrate the effects 
of antibiotic therapy within 24 hours on mortality. Roghmann (Roghmann 2000) 
did not to find any relationship between survival and the administration of effective 
antibiotic therapy within 48 h after SAB onset. 
Ammerlaan (Ammerlaan, Seifert et al. 2009) conducted a retrospective study of 
SAB in 9 European countries. Inadequate therapy was common (28% of the 
patients), but the investigators found no association between inadequate treatment 
and 30-day mortality. 
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Table 3. 
Predictive factors for death (28 day) among patients with invasive Staphylococcus aureus 
infection 
Fatality rate  Factor 
With 
factor(%) 
Without 
factor(%) 
OR 
(95% CI) 
p 
 
Patient characteristic 
Male sex 19/92(21) 11/65(17) 1.28(0.56-2.91) 0.710 
Age >65 years 25/92(27) 5/65(8) 4.48(1.1-12.43) 0.003 
Heart vitium 8/15(54) 21/136(15) 6.26(2.05-19.10) 0.004 
Coronary disease 12/34(35) 18/105(14) 2.64(1.11-6.28) 0.052 
Alcohol abuse 5/11(46) 25/135(18) 3.67(1.04-12.98) 0.098 
Infection characteristic 
Community-acquired infection 11/80(14) 19/77(25) 0.49(0.21-1.11) 0.134 
Healthcare-associated infection 7/28(25) 23/129(18) 1.54(0.58-4.04) 0.529 
Nosocomial infection 12/49(24) 18/108(17) 1.62(0.71-3.70) 0.348 
Bacteraemia 30/131(23) 0/26(0)  0.005 
Severe sepsis 27/50(54) 3/107(3) 40.7(11.4-145.7) <0.001
Complicated bacteraemia 17/53(32) 13/104(12) 3.29(1.46-7.50) 0.007 
Bacteraemia without focus 10/32(31) 20/125(16) 2.39(0.98-5.80) 0.096 
Arthritis 0/23(0) 30/134(22)  0.010 
Endovascular infection 6/11(54) 24/146(16) 6.10(1.72-21.61) 0.014 
Osteomyelitis other than 
spondylitis 
0/13(0) 30/144(21)  0.070 
Respiratory infection 4/8(50) 26/149(17) 4.73(1.11-20.15) 0.036 
Treatment characteristic 
Adequate empirical antibiotic 
therapy 
28/132(21) 0/15(0)  0.070 
Antibiotic therapy within 24 
hours 
23/116(20) 3/18(17) 1.24(0.33-4.63) >0.900
 
Recurrences were not included in the analysis (i.e. the first episode was not included if a patient 
had several episodes). 
 
The prevalence of resistant isolates in our area is low, as we had no MRSA cases. 
We could not evaluate how treatment with a betalactame antibiotic or a 
glycopeptide antibiotic affects outcome because we had so few patients with the 
latter regime. It is a well-known fact that vancomycin therapy clears bacteraemia 
less effectively than betalactames (Khatib, Johnson et al. 2006). 
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Patients with bacteraemia, complicated bacteraemia and severe sepsis all had high 
mortality rates. Only severe sepsis and systolic blood pressure were independent 
factors for mortality in the multivariable regression model. This highlights the 
importance of the initial assessment and early care of ISA patients. 
Recurrence (Paper II) 
We observed 13 recurrences, i.e. a recurrence rate of 9.3%, the same as reported by 
Chang (Chang, Peacock et al. 2003) for SAB. Patients with line-associated 
infections have a high relapse rate if the IV line is not replaced. In 3 of 5 of our 
patients with recurrent line-associated infections the IV line was not replaced. 
Some researchers report higher relapse rates with shorter antibiotic therapy 
(Verhagen, van der Meer et al. 2003) others not (Chang, Peacock et al. 2003; 
Johnson, Almoujahed et al. 2003). We did not find any differences in relapse rate 
among patients with shorter antibiotic therapy than 14 days as compared with 
patients with therapy exceeding 14 days. The issue concerning the length of 
antibiotic treatment may distract attention from the most important factor: 
identifying and eradicating the focus/source of infection. There was no difference 
among bacteraemia cases versus non-bacteraemia cases regarding the relapse rates 
in our study. There is no previous study on relapse rate among ISA patients. 
 
Sequelae (Paper II) 
At follow-up one month after the antibiotic therapy ended, forty-four patients had 
not experienced full recovery. Patients with osteomyelitis other than vertebral 
suffered sequelae in 69% of the cases, and 60% of arthritis cases reported 
remaining symptoms in this short-term follow-up. Davis (Davis 2005) summarized 
that 40-50% of patients had residual joint dysfunction with highest risk in the older 
population. These unacceptably high rates of failure demand measures for 
identifying factors important to improvement in management. This is a joint 
responsibility of various medical specialties. 
 
agr (Paper II) 
The distribution of agr groups was not different in different disease entities. Jarraud 
(Jarraud, Mougel et al. 2002) found an association between type of disease and agr 
group for toxin-mediated diseases and endocarditis. However, the relevant factor 
was the phylogenetic group, as determined with AFLP (Amplified Fragment 
Length Polymorphism), in the type of human disease, which is in accordance with 
our results. Fowler (Fowler, Nelson et al. 2007) found an association between 
bacterial clonality, based on MLST, multilocus sequence typing, and hematogenous 
complications. Isolates within these clonal complexes were also implicated by use 
of spa, staphylococcal protein A, and SCCmec, staphylococcal chromosomal 
cassette, typing. 
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The humoral immune response in patients with ISA (Paper III) 
Antibody levels in all patients 
Great interindividual variations in antibody levels were seen, from 50 to 5,000 units 
against the same antigen in the same sample category, as reported previously 
(Colque-Navarro, Palma et al. 2000; Dryla, Prustomersky et al. 2005). As expected, 
the levels achieved in the second sample at the end of treatment were generally the 
highest, but the median levels varied relatively little between the three sampling 
occasions. With the exception of SSS, 40% to 95% of the patients reacted to a 
staphylococcal antigen, where lipase stimulated the highest number of patients, 
regardless of kinetic parameter measured. 
Antibody response and bacterial properties  
Bacterial strains belonging to agr groups I and II, produced significantly larger 
zones of haemolysis as compared with strains belonging to agr group III, indicating 
that there is a correlation between agr group and production of alpha-toxin. The 
zones of haemolysis were significantly correlated with levels of antibodies against 
alpha-toxin at presentation. We also found a significant correlation between agr 
group III and a low initial anti alpha-toxin antibody level (p<0.001). Söderquist 
(1993) reported that strains from patients with a positive antibody response to 
alpha-toxin showed a higher production of alpha-toxin. Most strains produce alpha-
toxin in vitro (Möllby 1983), while less is known about production in vivo. In the 
study by Söderquist (1993) alpha-toxin was detected in 8/41 patients with S. aureus 
septicaemia. Staphylococcus aureus global regulators agr, sarA, and sae 
coordinatedly control alpha toxin gene (hla) expression in vitro. Xiong (Xiong, 
Willard et al. 2006) demonstrated that sae appears to play a crucial role. 
 
Screening for tst among the strains revealed that 17% of the strains carried the tst 
gene with 90% of the tst-positive isolates belonging to agr group III (p<0.001). A 
correlation between occurrence of tst among the strains and absolute TST antibody 
levels (samples 1 and 2, p=0.002 and p<0.001 respectively) among the patients was 
found. agr-group III correlated to higher TST antibody levels. The proportion of 
tst-positive strains from clinical isolates varies between <20% and 90%, according 
to country and clinical background (Nagao, Okamoto et al. 2009). Nagao found 
75% tst-positive strains among MRSA isolates, mostly belonging to agr group II. 
The amounts of TST varied, and no correlation was seen with mutation within the 
agr-locus, so there must also be other factors determining the production of the 
toxin. 
 
We did not screen for the gene for SSS. However, in accordance with the antibody 
response to TST, differences were found between different strains. PGFE-group 2 
and agr-group I correlated with initial low levels of antibodies, as compared with 
agr-group II, which correlated with higher initial antibody levels. 
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The immune response to alpha-toxin, TST, and SSS is specific in the respect that it 
is correlated with strain specificity. 
 
Surprisingly, levels of antibodies to teichoic acid, a cellwall constituent expressed 
in all strains, correlated significantly with agr-group. Strains belonging to agr-
group I showed a positive serology response in 45% of the patients as compared 
with 78% of strains belonging to agr-group III. We did not find any correlation 
between disease presentation and agr-group, but 4/8 patients with respiratory 
infections were infected with strains belonging to agr-group III. 
Clinical outcome 
Patients with a fatal outcome displayed lower initial antibody levels for all 
antigens, and significantly for 4 antigens (Table 4). The same trend was noted in 
patients with complicated bacteraemia for 5 antigens, but not for TST, SEA and 
SSS. The mean age was significantly higher in the patients who died (79y vs. 63y, 
p=0.014). Patients with severe sepsis were also significantly older (75y vs. 60y, 
p<0.001), but no difference in mean age was registered in patients with complicated 
vs. uncomplicated bacteraemia (65y vs. 64y). We could not detect any significant 
differences in the time from start of symptoms to inclusion in the study, or to the 
first blood sample, in any group, although patients who died tended to have had 
shorter duration of symptoms. 
 
Table 4. 
The initial antibody levels presented as Relative Risk for different clinical outcomes 
Five antigens are shown, n=96 
  28 day mortality 
n = 10 
Severe sepsis 
n = 28 
Compl.bacteraemia
n = 32 
Antigen Ab level RR (95% CI) RR  RR (95% CI) 
TA Low 4.1(1.3-13.3) 1.6 2.2 (1.3-3.9) 
AT Low 1.5 0.6 1.6 
Lipase Low 4.3 (1.3-13.1) 1.1 2.1(1.2-3.7) 
SEA Low 3.6 (1.1-11.9) 1.2 0.8 
SSS Low 13.2 (1.7-99.7) 1.7 0.9 
ANY of 8 
antigens 
High 
Low 
0.2 (0.1-0.9) 
3.0 
0.9 
0.8 
1.0 
1.2 
 
One obvious explanation for the observation of lower antibody levels among 
patients with a fatal outcome is the age. Older people (>65y) develop a 
dysregulation of the humoral immunity, affecting quality and quantity of antibody 
response. They display lower levels of several antigens, notably the superantigens 
TST, SEA and SSS. Aging is associated with a shift in antibody isotype from IgG 
to IgM, and a decline in the activity of lymphocytes (Weksler 2000). 
 
To our knowledge, this is the first time an association has been found between fatal 
outcome and initial low antibody response in ISA, except for TST (Todd, Fishaut et 
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al. 1978; Vergeront, Stolz et al. 1983; Andrews, Parent et al. 2001). The 
significance of this observation is debatable. 
We cannot draw any conclusions concerning whether the observed correlation 
between low initial antibody levels and fatal outcome is of causative art or 
attributable to a general weak immune response. 
 
Colque-Navarro (Colque-Navarro, Soderquist et al. 1998) showed, in a study of S. 
aureus septicaemia that patients with a complicated course displayed lower 
antibody levels against alpha-toxin, teichoic acid, and lipase, not only at admission, 
but also during the first month. Verbrugh (Verbrugh, Peters et al. 1986) 
demonstrated the opposite, patients with a complicated course were more 
frequently positive in serology against alpha-toxin, teichoic acid, and peptidoglycan 
than patients with an uncomplicated course, and they displayed higher peak values. 
However, this was not shown for the initial antibody response. Several studies 
relate higher antibody response with a complicated course (Julander, Granstrom et 
al. 1983; Christensson, Espersen et al. 1985), based on repeated samples and peak 
values. 
 
Patients with a previous history of ISA (n=14) had a trend toward a lower risk of a 
fatal outcome and complicated bacteraemia. They were significantly less prone to 
developing severe sepsis, and their initial antibody response to alpha-toxin tended 
to be higher (83% had an initial high response compared to 31% in patients with no 
previous ISA). There was no bacteraemic endovascular infection registered among 
patients with a previous history of ISA. 
This is in accordance with Ruotsalainen (Ruotsalainen, Karden-Lilja et al. 2008) 
who found an elevated initial ASTA titer significantly more often among injecting 
drug users without endocarditis than with endocarditis in a study of SAB (44% vs. 
6%). 
 
Antibody response in healthy individuals (Paper IV) 
Antibody levels in relation to age 
The median value was lower at a higher age; significant differences were only 
found for Clumping factor B. An exception was seen for antibodies against TST, 
where the median levels were twice as high in individuals above 65 y compared 
with individuals below 65 y, although there were no significant changes due to the 
great variation. Several studies have shown that antibody levels in the healthy 
elderly decrease with age (Granstrom, Julander et al. 1983; Julander, Granstrom et 
al. 1983; Dryla, Prustomersky et al. 2005). 
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Antibody levels in relation to sex 
There were no differences seen in the antibody levels of men as compared with 
women. 
Antibody levels in relation to colonization of the nares 
Individuals carrying S. aureus in the nose displayed higher antibody levels against 
all antigens except Efb (Table 5). For five of the analysed antigens, the difference 
was statistically significant, e.g. the antibody levels against Extracellular adherence 
protein were three times higher in healthy individuals colonized with S. aureus than 
in individuals not colonized. 
 
Table 5 
Antibody levels in colonized individuals versus non-colonized 
(median values) 
Antigen 
 
Colonized 
n=26 
Non colonized 
n=89 
p 
Surface antigens    
Teichoic acid 912 422 0.01 
ClfA 170 134 0.24 
ClfB 191 163 0.09 
Bsp 233 161 0.07 
Extracellular proteins    
Alpha toxin 325 165 0.06 
Lipase 364 176 0.01 
SEA 483 271 0.01 
TST 1043 378 0.02 
SSS 161 115 0.28 
Efb 394 438 0.40 
Eap 268 85 0.01 
 
None of the individuals showing low antibody levels to more than four antigens 
were colonized (p=0.04), and six out of eleven of the individuals with high 
antibody levels against 4-5 antigens were colonized with S. aureus (p=0.02). 
 
It has been demonstrated that carriers show higher levels of antibodies against TST, 
SEA, ClfA and ClfB (Wertheim, Walsh et al. 2008; Verkaik, de Vogel et al. 2009). 
The immune response does not protect from colonization. However, Clark (Clarke, 
Brummell et al. 2006) found higher levels of reactive IgG to iron-responsive 
surface determinant (Isd) A and Isd H from non-carriers, and he also showed 
beneficial effects of vaccination with Isd A or H in an animal model against nasal 
carriage. So colonization could be the result of a failing humoral immune response, 
or the humoral immune response could be a consequence of the colonization. The 
work of Cole 2001 (Cole, Tahk et al. 2001) is in favour of the latter hypothesis, 
demonstrating that colonized individuals had defects in their local innate immunity 
towards S. aureus. 
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We showed higher antibody levels in carriers for all three superantigens (Sag), 
TST, SEA and SSS, although not significant for the latter. This is demonstrated 
repetitively in studies concerning antibody response in correlation to carrier-state. 
What are the Sag doing for the bacterium in the context of nasal colonization? It is 
certainly not to induce systemic toxic shock in the host. The most likely role of Sag 
is during the early stages of infection when the very low levels of Sag activate only 
local T cells. One possible advantage of T-cell activation at the infection site might 
be to produce cytokines such as IL-2, IFN-γ, and TFN-α that suppress local 
inflammation (Fraser and Proft 2008). Vojtov (Vojtov, Ross et al. 2002) revealed a 
remarkable difference in local inflammation in hairless mice subcutaneously 
injected with a TST producing strain of S. aureus compared with an isogenic 
knockout strain. After 4 days, mice injected with Sag producing strain produced no 
significant inflammatory lesion, while the Sag knockout strain produced a purulent 
open abscess characteristic of a subcutaneous S. aureus infection. The authors 
suggested that this outcome was due to a global regulatory effect of TST on the 
expression of other staphylococcal exoproteins, but alternatively the lack of an 
inflammatory response may have been caused by T-cell activation and suppression 
of innate mechanisms. 
 
Carriers have better prognosis than non-carriers in nosocomial bacteraemia 
(Wertheim, Vos et al. 2004), and Holtfreter (Holtfreter, Roschack et al. 2006) have 
explained the improved prognosis in terms of the increased levels of preformed 
antibodies. For toxins such as TST and SEA the existence of antibody levels are 
clearly protective (Holtfreter, Roschack et al. 2006; Verkaik, de Vogel et al. 2009). 
 
High or low levels of antibodies 
Dryla (Dryla, Prustomersky et al. 2005) stated that most of the antibodies were 
produced against surface antigens. In our study the protein surface antigens used 
did not appear to produce particularly high levels, since ClfA antibodies had to be 
tested for at an initial dilution of 1/250 and ClfB and Bsp antibodies at the lowest 
initial dilution of 1/125. 
Some individuals showed low antibody levels against several antigens. None of the 
individuals showing low antibody levels to more than four antigens were colonized 
(p=0.04). Similarly, there was a skewed distribution of the number of antigens 
against which certain individuals showed high levels of antibodies. 
Antibodies against the extracellular proteins alpha-toxin, lipase, enterotoxin A and 
extracellular adhesive protein more often were found in the same individuals, most 
often together with the surface bound teichoic acid. 
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General summary 
 
The magnitude of the clinical problem caused by Staphylococcus aureus is not fully 
recognised. Incidence and prognosis are unknown in Sweden. Melander (Melander, 
Burman et al. 2007) tried to describe the consequences of rising MRSA prevalence 
in terms of costs, both medical expenses and human suffering. However, she could 
not rely on adequate incidence figures. Hence her estimation of bacteraemia 
attributable to S. aureus was a rough extrapolation. 
 
The intention of our studies was to describe the epidemiology of serious infections 
of S. aureus in a prospective population-based study, to describe mortality, 
recurrence, and functional impairment, and to detect humoral immune response 
conferring protection/susceptibility to infection and outcome. 
 
The incidence of ISA of 33.9/100,000 inhabitants is higher than that for 
pneumococcal disease, 19.3/100,000 population 2008 (SMI 2009). Streptococcus 
pneumoniae is a pathogen subject to mandatory reporting. Out of the cases of ISA, 
49% were classified as community-acquired, 32% as nosocomial and 19% as health 
care-associated. 
 
Haemo and peritoneal dialysis patients showed a several hundred-fold relative risk 
of acquisition, which highlights the need for individual risk assessment and 
preventive measures. It was also clear that the clinical presentation is a challenge to 
the clinician, with nearly one quarter of the patients having no fever. 
 
In spite of improvement in diagnosis and treatment of ISA, the mortality figures are 
still high, and study number two demonstrated an overall mortality of 19.1% (28-
day mortality), with an annual population mortality of 5.9/100,000. Laupland 
(Laupland, Ross et al. 2008) reported an annual mortality in Canada in bacteraemia 
due to S. aureus during 2000-2006 of between 4 and 5/100,000, with exception of 
2005, when it reached nearly 6/100,000. This was in spite of a substantial number 
of cases with MRSA with known higher mortality, and with seemingly a higher 
prevalence of risk groups. These findings underscore the importance of not 
translating incidence and mortality figures for serious S. aureus infections from one 
area to another uncritically. Perhaps, for a key pathogen like S. aureus, each region 
should actively monitor incidence and mortality data. 
 
The most common diagnoses, irrespective of primary or secondary focus diagnosis, 
were soft tissue infection, bacteraemia without focus, infections of intravenous 
lines, and joint/bone infections, as reported by others (Laupland, Church et al. 
2003). Patients with complicated bacteraemia (32%) had mortality rates of 32%, 
and patients with severe sepsis (30%) of 54%. 
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Patients with bacteraemia without known source, patients with respiratory 
infections, and patients with endovascular infections had the highest mortality 
which is in agreement with the findings of others (Mylotte and Tayara 2000). 
Only severe sepsis and systolic blood pressure were independent risk factors for 
mortality in a multivariable regression model. This underlines the importance of 
early recognition and of the initial assessment and care of ISA patients. 
 
A signum of S. aureus is its capacity to cause metastatic infections and relapses. 
We demonstrated a relapse rate of 9.3%, and a rate of remaining symptoms after 
the conclusion of antibiotic treatment of 34%. In some diagnoses, e.g. arthritis, 
60% of the patients reported sequelae, indicating a potential for improvement. This 
is a joint responsibility for various medical disciplines. 
 
The frequency of different agr (accessory gene regulator), groups was not 
correlated to clinical disease. agr is a key regulator of virulence in S. aureus, and 
Jarraud (Jarraud, Mougel et al. 2002) found an association between type of disease 
and agr group for toxin-mediated diseases and endocarditis. 
 
It is generally believed that the antibody response toward S. aureus is not 
protective. An individual could suffer from repeated infections in spite of 
demonstrable antibody levels. There is no vaccine available, and passive 
immunprophylaxis has not been successful. 
 
The present study on the humoral immune response in ISA showed a great 
variability in antibody levels among patients. People over 65 y react to a lesser 
extent and those with concurrent illnesses, e.g. patients with rheumatoid arthritis, 
displayed lower levels. Patients with fatal outcome produced lower amounts of 
antibodies to all tested antigens, and significantly to 4 antigens. The same trend was 
noted for patients with a complicated course of infection in 5 antigens in the initial 
serum sample. Others (Verbrugh, Peters et al. 1986) have reported higher antibody 
levels among patients with complicated bacteraemia, but the initial serum answer 
was not considered. 
 
The significance of these findings is not clear. Possibly this is part of a weakened 
polyclonal reaction owing to age and concurrent diseases, or a specific response to 
some antigens may be missing in some individuals. 
 
Healthy individuals display variable antibody levels, and individuals colonized with 
S. aureus (carriers) in the nares show higher antibody levels than non-carriers 
toward some antigens (Verkaik, de Vogel et al. 2009). Being a carrier of S. aureus 
is a well-known risk factor for ISA, but carriers have a better outcome than non-
carriers with ISA (Wertheim, Vos et al. 2004), which may be explained in terms of 
preformed antibodies (Holtfreter, Roschack et al. 2006). 
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It was demonstrated in the study of healthy individuals that carriers had higher 
levels to all 11 antigens tested, and significantly to 5. Some individuals displayed 
high antibody levels to several antigens, and some showed low antibody levels to 
several antigens. Identifying protective immune response in clinical studies is 
important in order to develop vaccine candidates. 
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Conclusions 
 
 
 
• The annual incidence of invasive Staphylococcus aureus infections was 33.9 
cases/100,000 population. 
 
• Haemodialysis (relative risk 291), and peritoneal dialysis (relative risk 204) 
were the predisposing conditions with highest risk. 
 
• Soft tissue infection, bacteraemia without focus, arthritis, and line-associated 
infection were the most common clinical presentations, and the spectrum of 
signs and symptoms were wide, with one quarter of the patients reporting no 
fever. 
 
• During the first 28 days, 30 patients (19.1%) died, with mortality rates for 
complicated bacteraemia and severe sepsis of 32% and 54% respectively. 
 
• Patients with bacteraemia without focus, patients with respiratory infections, 
and patients with endovascular infections had the highest mortality. 
 
• Recurrence and residual symptoms were common, 9.3% and 34% 
respectively. 
 
• The frequency of different agr, accessory gene regulator, groups was not 
different in different disease presentations. 
 
• The antibody response showed great variability in relation to age, concurrent 
illness, strain properties and severity of infection. Patients with fatal outcome 
and complicated bacteraemia had lower antibody levels at the time of 
diagnosis. 
 
• Healthy individuals colonized with S. aureus in the nares (carriers) displayed 
higher antibody levels than non-carriers. 
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Future perspectives 
 
S. aureus is a leading, possible the leading, pathogen in bacteraemia. It is 
unsatisfactory not to know the incidence and complication rates in a given region. 
Mandatory reports on occurrence in invasive diseases are warranted. 
 
Risk groups with high rates of infection could be identified and headed prophylaxis 
such as nasal decolonization should be tried (von Eiff, Becker et al. 2001). 
 
We showed that the only independent predictors for mortality were severe sepsis 
and low systolic blood pressure. This highlights the importance of early recognition 
and treatment of serious infections. Several campaigns for improving survival in 
sepsis have been launched in recent years (Townsend, Schorr et al. 2008), but 
implementation in clinical practice is still deficient. 
 
Algorithms for early recognition of sepsis patients stress the use of physiological 
parameters such as respiratory rate, percutaneus saturation, and blood pressure. 
Patients with invasive infection due to S. aureus are often elderly and with 
concurrent diseases. This complicates the evaluation of physiological parameters, 
and opens up for misinterpretation. There is a clear need for better diagnostic tools 
in identifying patients with invasive infections. 
 
Bacteraemic patients make up the majority of cases with invasive infections. Blood 
culture is time-consuming. Faster methods with PCR in detection on bacteraemia 
are under development (Dierkes, Ehrenstein et al. 2009). Small colony variants 
constitute a subpopulation of bacteria with distinctive phenotypic and pathogenic 
traits. They survive intracellular and in biofilms, and thus responding poorly to 
antibiotic therapy. Microbiological laboratories need to be more attentive 
diagnosing those strains (Proctor, von Eiff et al. 2006). 
 
In our study only 18% of the patients were cared for initially at the Department for 
Infectious Diseases. Many of the patients were first seen by doctors not committed 
to infectious disease practice. Outcome of S. aureus bacteraemia may be improved 
by consultation with an infectious disease consultant (Rieg, Peyerl-Hoffmann et al. 
2009), and this practice must be encouraged. We also demonstrated the 
unacceptably high rate of sequelae, e.g. 60% of the arthritis patients. This stresses 
the joint responsibility and the need for cooperation between different specialists 
(Stenmark 2009). 
 
S. aureus has a propensity to cause metastatic infections, especially endocarditis. 
Echocardiography should be part of the standard care (Rosen, Fowler et al. 1999). 
Vos (Vos 2009) has shown the value of PET (Positron Emissions Tomography) 
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screening in detection of metastatic foci in S. aureus bacteraemia. Patients 
undergoing PET examination had both lower relapse rates and lower mortality 
rates. Clinical examination is not enough, since up to one third of metastatic foci 
have no localizing signs or symptoms. 
 
Focus identification and eradication are of key importance in management of S. 
aureus bacteraemia, as is timely and adequate antibiotic treatment. Beta-lactam 
antibiotics, especially penicillins, are regarded as first line therapy. However, it is 
known that cellwall active antibiotics have a slow killing time of large inoculates of 
bacteria. 
 
The repeated demonstration that vancomycin (the current “gold standard” for the 
treatment of MRSA infection) is associated with a significantly worse outcome 
when used in MSSA infection (Fowler, Sanders et al. 1998; Chang, Peacock et al. 
2003; Stryjewski, Szczech et al. 2007) emphasizes the need for drugs that are 
equally effective for the treatment of MSSA and MRSA infections. 
 
Combined anti-inflammatory and antibiotic treatment down-regulates the severity 
of septic arthritis (Sakiniene, Bremell et al. 1996). Addition of corticosteroids to 
antibiotic treatment in staphylococcal arthritis should be evaluated. 
 
The resistance potential of S. aureus not only call for new antibiotic classes but also 
non-antibiotic treatment. In vitro studies on interfering with the quorum-sensing 
control in S. aureus suggest this possibility (Otto 2004). There is a renewed interest 
in bacteriophage therapy in various clinical settings (Deresinski 2009). 
Bacteriophages were used for the treatment of patients with bacterial infections 
mainly in the former Soviet republics for more than nine decades, but no adequate 
clinical trials of the safety and efficacy of the treatment have been reported. This 
also applies to the Russian experience with antistaphylococcal hyperimmune 
plasma and immunoglobin (Kelly 2000). 
 
There is no commercial vaccine available. A pentavalent vaccine (PentaStaph™) is 
undergoing clinical trials. This vaccine is based on capsular polysaccharides types 5 
and 8, the cell wall antigen type 336, Panton-Valentine Leukocidin, and alpha 
toxin. This is a promising vaccine candidate, especially as compared with 
StaphVAX, which was based only on capsular polysaccharides type 5 and 8. 
Pressure to develop vaccines against staphylococci will be driven by the increasing 
spread of antibiotic resistance. 
 
The humeral immune response is still not well described in large cohorts of patients 
with S. aureus infections. Such surveys are now in progress (Wertheim 2009). 
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Svensk sammanfattning 
 
Gula stafylokocker, Staphylococcus aureus, är en vanlig orsak till blodförgiftning, 
bakteremi. Bakterien har utvecklat resistens mot ett flertal antibiotikagrupper och i 
många länder ökar såväl kostnader för som dödlighet i svåra 
stafylokockinfektioner. Än så länge är problemet med resistenta stafylokocker litet 
i Sverige. Hur stort problemet är med icke-resistenta stafylokocker vet vi inte, 
bakterien är inte anmälningspliktig och statistik över antal bakteremier och död till 
följd av detta finns inte. 
 
Förutom att orsaka bakteremi har bakterien egenskapen att orsaka nedslag av 
infektionen i olika delar av kroppen. Mest fruktat är nedslag på hjärtklaffarna, med 
hög dödlighet som följd. Andra organ som kan drabbas är leder, skelett och inre 
organ. Återkommande infektioner förekommer och resttillstånd med bestående 
handikapp är inte ovanligt. 
 
Det finns inget vaccin. Mot andra bakterier, som t ex pneumokocker, finns 
effektiva vacciner med antikroppssvar som skyddar mot allvarlig sjukdom. Så gott 
som alla människor har påvisbara nivåer av antikroppar mot stafylokocker vid 
provtagning. Trots detta skyddar inte dessa antikroppar mot infektion, oklart varför. 
 
Syftet med avhandlingen var att ta reda på hur vanligt det är med allvarliga 
stafylokockinfektioner och att hitta människor som har högre risk att drabbas. 
Ytterligare avsikt var att beskriva dödlighet, återfall och resttillstånd, samt att 
jämföra antikroppssvar hos patienter med stafylokockinfektion och friska. 
 
I delstudie I visade vi att ca 34 fall av allvarlig stafylokockinfektion inträffar per 
100 000 invånare och år. Detta är betydligt högre än t ex allvarliga 
pneumokockinfektioner som drabbar färre än 20 per 100 000 och år. Vissa 
patientkategorier, som dialyspatienter, hade nästan en 300 ggr högre risk än 
normalbefolkningen att insjukna. 
 
I delstudie 2 visade vi att dödligheten under den första månaden efter infektion var 
knappt 20%, dvs. 1 av 5 dör. Patienter med hjärtklaffsinfektion, lunginflammation 
och oförklarad blodförgiftning hade den högsta dödligheten. Återfall inträffar i 
knappt 10% av fallen. Det är vanligt med resttillstånd, t ex hade 60%, av patienter 
med ledinfektion någon form av problem en månad efter avslutad 
antibiotikabehandling. 
 
I delstudie 3 visade vi att individer med allvarlig stafylokockinfektion har mycket 
varierande nivåer av antikroppar. En orsak är åldern, patienter över 65 år har lägre 
halter. De som dog eller hade ett komplicerat sjukdomsförlopp hade lägre nivåer. 
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Detta skulle kunna betyda att antikroppar trots allt har betydelse för försvar mot 
stafylokockinfektion. 
 
I delstudie 4 undersökte vi friska människor och förutom blodprov för antikroppar 
tog vi också en näsodling för stafylokocker. Det är vanligt att i övrigt friska 
personer har stafylokocker i näsöppningen. Vi visade att även hos friska varierade 
antikroppsnivåerna mycket, men generellt var nivåerna lägre än hos patienter. 
Personer som var näsbärare av bakterien hade högre nivåer av alla testade 
antikroppar än icke-näsbärare. 
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